Skip to main content

Update on Stem Cell Therapies for Parkinson's Disease

August 15, 2019

This is an archived file of an event that took place on Thursday, August 15, 2019.

Our panelists discuss the types of stem cells, the status of stem cell-derived therapies for Parkinson's, and how scientists use stem cells as research tools. The speakers and our staff answer questions from the audience as well.

Webinar Details


Thursday, August 15, 2019


1 hr


12:00 pm ET

  • Continuing Medical Education Information for Health Care Professionals

    MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

    Date of Original Release: August 15, 2019
    Date Credit Expires: August 15, 2021

    Learning Objectives

    At the conclusion of this course, participants should be able to:

    • Define what a stem cell is.
    • Describe different types of stem cells, including embryonic, adult and induced pluripotent.
    • Summarize how researchers can use stem cells.
    • Discuss ongoing stem cell research in Parkinson’s disease.
    • Understand how clinics offering unproven stem cell therapies differ from ongoing FDA-approved stem cell clinical trials.
    Target Audience

    This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

    Oakstone Publishing designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing planners, content reviewers, and editorial staff disclose no relevant commercial interests.


    Brian Fiske, PhD
    Senior Vice President, Research Programs
    The Michael J. Fox Foundation
    Nothing to disclose

    Claire Henchcliffe, MD, DPhil
    Professor of Neurology
    Weill Cornell Medical College
    Disclosures: Advisory role -- Prevail Therapeutics; US WorldMeds; Amneal Pharmaceuticals

    Julia Kaye, PhD
    Scientific Program Leader
    Center for Systems and Therapeutics, Gladstone Institutes
    Nothing to disclose

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.